Morphology of the adult and immatures of a striking new species of leaf-mining Brachys Dejean from Brazil (Buprestidae, Agrilinae)

Adult and immature stages of a new species, Brachys cleidecostae sp. nov., are described and illustrated. This species represents the first leaf-mining buprestid with two broad, prominent horn-like apophyses on vertex, resembling broad horns. The material was collected within unusual shaped leaf mines in Alibertia sessilis (Vell.) K. Schum (Rubiaceae), a native species from Brazilian Savanna (Cerrado). This is the first record of Brachys associated with a host plant of family Rubiaceae

The systematics of Dysmorphocerinae (Cantharidae) based on larvae

Dysmorphocerinae is a subfamily of Cantharidae erected for a group of genera with a mainly gondwanan distribution whose adult forms could not be reliably assigned to any other subfamily. The systematic position and monophyly of Dysmorphocerinae remains questionable, as recent molecular and morphological studies have produced conflicting results. Despite the importance of immature morphology for characterising lineages of Cantharidae, so far, the larvae of only two dysmorphocerine species had been briefly described: Neoontelus sp., from New Zealand, and Afronycha picta (Wiedemann), from South Africa. Their morphologies considerably differ from one another, and the larvae cannot be readily attributed to any subfamily, as usually occurs with cantharid larvae. Here, we fully describe for the first time the larvae of Asilis Broun (New Zealand) and Plectonotum laterale Pic (Brazil) and redescribe Neoontelus Wittmer (New Zealand). We also diagnose larvae of Heteromastix Boheman (Australia) and A. picta. Dysmorphocerinae cannot be clearly diagnosed because each genus has a unique combination of features, though Neoontelus is the most divergent. We conclude that the Dysmorphocerinae may not be monophyletic with Plectonotum laterale, Asilis, Neoontelus, Heteromastix showing a closer relationship to Malthininae and Afronycha more aligned with Silinae or Cantharinae. The double gland openings present on the body of Neoontelus reported by are reinterpreted as a complex character involving a single posterior pore linked to a gland and an anterior sensillum that may serve as a trigger for the release of defensive chemicals. These are also reported in Asilis and Heteromastix and may be a potential synapomorphy for part of the Dysmorphocerinae. Neoontelus has a series of unique features, including a cotyliform glandular pore on abdominal segment IX.The São Paulo Research Foundation, The Foundation of Support to the University of São Paulo and Fundação de Amparo e Desenvolvimento da Pesquisa as well as funded in part by Strategic Science Investment Funding for Crown Research Institutes from the Ministry of Business, Innovation and Employment’s Science and Innovation Group.https://brill.com/view/journals/ise/ise-overview.xmlhj2023Zoology and Entomolog

Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19 pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-alpha 2 in 10 patients: IFN-alpha 2 only in three, IFN-alpha 2 plus IFN-omega in five, and IFN-alpha 2, IFN-omega plus IFN-beta in two; IFN-omega only in nine patients). Seven children (3.8%) had Abs neutralizing at least 10 ng/ml of one IFN, whereas the other 12 (6.6%) had Abs neutralizing only 100 pg/ml. The auto-Abs neutralized both unglycosylated and glycosylated IFNs. We also detected auto-Abs neutralizing 100 pg/ml IFN-alpha 2 in 4 of 2,267 uninfected children (0.2%) and auto-Abs neutralizing IFN-omega in 45 children (2%). The odds ratios (ORs) for life-threatening COVID-19 pneumonia were, therefore, higher for auto-Abs neutralizing IFN-alpha 2 only (OR [95% CI] = 67.6 [5.7-9,196.6]) than for auto-Abs neutralizing IFN-. only (OR [95% CI] = 2.6 [1.2-5.3]). ORs were also higher for auto-Abs neutralizing high concentrations (OR [95% CI] = 12.9 [4.6-35.9]) than for those neutralizing low concentrations (OR [95% CI] = 5.5 [3.1-9.6]) of IFN-omega and/or IFN-alpha 2

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

Publisher Copyright: © 2021 The Authors, some rights reserved.Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/ml; in plasma diluted 1:10) of IFN-alpha and/or IFN-omega are found in about 10% of patients with critical COVID-19 (coronavirus disease 2019) pneumonia but not in individuals with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-alpha and/or IFN-omega (100 pg/ml; in 1:10 dilutions of plasma) in 13.6% of 3595 patients with critical COVID-19, including 21% of 374 patients >80 years, and 6.5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1124 deceased patients (aged 20 days to 99 years; mean: 70 years). Moreover, another 1.3% of patients with critical COVID-19 and 0.9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-beta. We also show, in a sample of 34,159 uninfected individuals from the general population, that auto-Abs neutralizing high concentrations of IFN-alpha and/or IFN-omega are present in 0.18% of individuals between 18 and 69 years, 1.1% between 70 and 79 years, and 3.4% >80 years. Moreover, the proportion of individuals carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10,778 uninfected individuals: 1% of individuals 80 years. By contrast, auto-Abs neutralizing IFN-beta do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over 80s and total fatal COVID-19 cases.Peer reviewe

Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

Life-threatening `breakthrough' cases of critical COVID-19 are attributed to poor or waning antibody response to the SARS- CoV-2 vaccine in individuals already at risk. Pre-existing autoantibodies (auto-Abs) neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in unvaccinated individuals; however, their contribution to hypoxemic breakthrough cases in vaccinated people remains unknown. Here, we studied a cohort of 48 individuals ( age 20-86 years) who received 2 doses of an mRNA vaccine and developed a breakthrough infection with hypoxemic COVID-19 pneumonia 2 weeks to 4 months later. Antibody levels to the vaccine, neutralization of the virus, and auto- Abs to type I IFNs were measured in the plasma. Forty-two individuals had no known deficiency of B cell immunity and a normal antibody response to the vaccine. Among them, ten (24%) had auto-Abs neutralizing type I IFNs (aged 43-86 years). Eight of these ten patients had auto-Abs neutralizing both IFN-a2 and IFN-., while two neutralized IFN-omega only. No patient neutralized IFN-ss. Seven neutralized 10 ng/mL of type I IFNs, and three 100 pg/mL only. Seven patients neutralized SARS-CoV-2 D614G and the Delta variant (B.1.617.2) efficiently, while one patient neutralized Delta slightly less efficiently. Two of the three patients neutralizing only 100 pg/mL of type I IFNs neutralized both D61G and Delta less efficiently. Despite two mRNA vaccine inoculations and the presence of circulating antibodies capable of neutralizing SARS-CoV-2, auto-Abs neutralizing type I IFNs may underlie a significant proportion of hypoxemic COVID-19 pneumonia cases, highlighting the importance of this particularly vulnerable population

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies

SignificanceThere is growing evidence that preexisting autoantibodies neutralizing type I interferons (IFNs) are strong determinants of life-threatening COVID-19 pneumonia. It is important to estimate their quantitative impact on COVID-19 mortality upon SARS-CoV-2 infection, by age and sex, as both the prevalence of these autoantibodies and the risk of COVID-19 death increase with age and are higher in men. Using an unvaccinated sample of 1,261 deceased patients and 34,159 individuals from the general population, we found that autoantibodies against type I IFNs strongly increased the SARS-CoV-2 infection fatality rate at all ages, in both men and women. Autoantibodies against type I IFNs are strong and common predictors of life-threatening COVID-19. Testing for these autoantibodies should be considered in the general population

Immatures of Lamprosoma amethystinum Perty, 1832 (Chrysomelidae, Lamprosomatinae)

The genus Lamprosoma Kirby, 1818 includes 128 neotropical species and 54 of them are recorded from Brazil (Monros, 1960). The first species with a described larva was L. seraphinum Lacordaire. After that, larvae and pupae of three species were described: L. bicolor Kirby, 1818, L. chorisiae Monros, 1948 and L. azureum Germar, 1824. Fiebrig (1910) described the larva of L. seraphinum Lacordaire, collected on Teminalia hassleriana Chod. (Combretaceae) of Paraguay. Moreira (1913) described L. bicolor collected on Terminalia catappa L., in Rio de Janeiro. According to him, this tree was introduced from Molucas Islands, in Oceania. He also considered it probable that L. bicolor lived on one native species of Terminalia or on another species of Combretaceae and adaptated itself to live on Terminalia catappa. Monros (1949) described L. chorisiae collected on Chorisia speciosa and Ch. insignis [ Ceiba speciosa (A. St.-Hil., A. Juss. & Cambess.) Ravenna and Ceiba insignis (Kunth) P. E. Gibbs & J. Semir] (Bombacaceae) ("" palos borrachos"") in Tucuman. Caxambu and Almeida (1999) described L. azureum collected on Psidium cattleianum Sabine (Myrtaceae)(""araca""), in Parana state. Herein, the larva and pupa of L. amethystinum collected on Terminalia catappa amendoeira-da-praia"", "" chapeu-de-sol"") in Campinas, Sao Paulo state, are described and illustrated

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.

Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or -ω (100 pg/mL, in 1/10 dilutions of plasma) in 13.6% of 3,595 patients with critical COVID-19, including 21% of 374 patients > 80 years, and 6.5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1,124 deceased patients (aged 20 days-99 years; mean: 70 years). Moreover, another 1.3% of patients with critical COVID-19 and 0.9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-β. We also show, in a sample of 34,159 uninfected subjects from the general population, that auto-Abs neutralizing high concentrations of IFN-α and/or -ω are present in 0.18% of individuals between 18 and 69 years, 1.1% between 70 and 79 years, and 3.4% >80 years. Moreover, the proportion of subjects carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10,778 uninfected individuals: 1% of individuals <70 years, 2.3% between 70 and 80 years, and 6.3% >80 years. By contrast, auto-Abs neutralizing IFN-β do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over-80s, and total fatal COVID-19 cases

Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants.

We conducted a genome-wide association study testing single nucleotide polymorphisms (SNPs) and copy number variants (CNVs) for association with early-onset myocardial infarction in 2,967 cases and 3,075 controls. We carried out replication in an independent sample with an effective sample size of up to 19,492. SNPs at nine loci reached genome-wide significance: three are newly identified (21q22 near MRPS6-SLC5A3-KCNE2, 6p24 in PHACTR1 and 2q33 in WDR12) and six replicated prior observations (9p21, 1p13 near CELSR2-PSRC1-SORT1, 10q11 near CXCL12, 1q41 in MIA3, 19p13 near LDLR and 1p32 near PCSK9). We tested 554 common copy number polymorphisms (>1% allele frequency) and none met the pre-specified threshold for replication (P < 10(-3)). We identified 8,065 rare CNVs but did not detect a greater CNV burden in cases compared to controls, in genes compared to the genome as a whole, or at any individual locus. SNPs at nine loci were reproducibly associated with myocardial infarction, but tests of common and rare CNVs failed to identify additional associations with myocardial infarction risk